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experimental xenogeneic graft-versus-host disease
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BACKGROUND: We investigated the ability of clinical-
grade enriched human regulatory T cells (Treg) to
attenuate experimental xenogeneic graft-versus-host
disease (GVHD) induced by peripheral blood mono-
nuclear cells (PBMNCs; autologous to Treg) infusion in
NSG mice, as well as verified their inability to induce
xenogeneic GVHD when infused alone.
STUDY DESIGN AND METHODS: Human Treg were
isolated from peripheral blood apheresis products with
a cell separation system (CliniMACS, Miltenyi Biotec
GmbH) using a two-step procedure (simultaneous CD8
and CD19 depletion followed by CD25-positive selec-
tion) in six independent experiments with six different
healthy volunteer donors. Sublethally (2.5 Gy) irradiated
NSG mice were given 2 ¥ 106 cytapheresis (PBMNC)
product cells intravenously (IV) without (PBMNC group)
or with 1 ¥ 106 Treg (PBMNC + Treg group), while other
NSG mice received 2 ¥ 106 enriched Treg alone (also in
IV; Treg group).
RESULTS: The first five procedures were successful at
obtaining a relatively pure Treg population (defined as
>50%), while the sixth procedure, due to a technical
problem, was not (Treg purity, 42%). Treg cotransfusion
significantly delayed death from xenogeneic GVHD in
the first five experiments, (p < 0.0001) but not in the
sixth experiment. Importantly, none of the mice given
enriched Treg alone (Treg group) experienced clinical
signs of GVHD, while, interestingly, the CD4+ cells
found in these mice 26 days after transplantation were
mainly conventional T cells (median CD25+FoxP3+
cells among human CD4+ total cells were only 2.1, 3.1,
and 12.2% in spleen, marrow, and blood, respectively).
CONCLUSIONS: Infusion of clinical-grade enriched
Treg delayed the occurrence of xenogeneic GVHD
without inducing toxicity in this murine model.
A
llogeneic hematopoietic cell transplantation
(allo-HCT) has been a potentially curative
option for many patients with hematologic
malignancies, acquired aplastic anemia, and
selected inherited blood or immune disorders. In patients
with hematologic malignancies, allo-HCT has been ini-
tially designed as a way to administer supralethal doses of
total body irradiation (TBI).1 However, an important part
of the efficacy of the procedure ismediated by the destruc-
tion of recipient tumor cells by donorT cells present in the
graft (graft-versus-tumor effects).2-5 Unfortunately, donor
immune cells present in the graft can also target recipient
ABBREVIATIONS: allo-HCT = allogeneic hematopoietic cell
transplantation; APC = allophycocyanin; BM = bone marrow;
HR = hazard ratio; PB = peripheral blood; TBI = total body
irradiation; TREC(s) = T-cell receptor excision circle(s);
Treg = regulatory T cells.
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tissues, causing graft-versus-host disease (GVHD), a life-
threatening complication of allo-HCT.6,7 The first year
after allo-HCT, establishment of graft-versus-host toler-
ance has been successful in 30% to 70% of the patients
given unmanipulated grafts from HLA-matched donors,
while the remaining patients experience chronic GVHD.8,9
It has been recognized since the late 1970s that tolerance
after allogeneic allo-HCT was largely due to “a suppressor
cell population” responsible for preventing GVHD by
blocking sensitization of donor T cells against the host.10
RegulatoryTcells (Treg)playacritical role in themain-
tenance of tolerance to self-antigens.11,12 Their develop-
ment and function require transcription factor FOXP3.
In humans, mutations in the FOXP3 gene cause Treg
deficiency, and a fatal disorder characterized by immune
dysregulation, polyendocrinopathy, enteropathy, and
X-linked inheritance (IPEX).13 In the past decade, much
attention has been paid to the potential role of Treg after
allo-HCT. In murine experimental GVHD models, admin-
istrationof highdoses ofTreg at the timeof transplantation
prevented acute GVHD without apparently impairing
graft-versus-tumor effects.14-16 Because thymic generation
ofTregwasmarkedly impaired, themajorityofTreg thefirst
month after allo-HCT in humans originated from expan-
sion ofmatureTreg contained in the graft and exhibited an
activated or memory phenotype.17 In addition, Treg from
patients with extensive chronic GVHDhad low telomerase
activity, suggesting that failure to activate Treg telomerase
activity after allo-HCT could restrict their proliferative
capacity and increase their susceptibility to apoptosis,
resulting in low Treg number and the development of
chronic GVHD.18 These observations are in line with
studies demonstrating a relativeTreg deficit in the gut (but
not in the stomach19) of patients with GVHD compared to
patients without GVHD20 and an association between low
Treg numbers and acute and/or chronic GVHD.21 In addi-
tion, Treg infusion allowed safe infusion of an otherwise
lethal dose of conventional T cells in the haploidentical
allo-HCT setting22 and possibly decreased acute GVHD in
adult patients given double unrelated cord blood trans-
plantation after reduced-intensity conditioning.23
We and others have recently developed a model of
xenogeneic GVHD, by infusing human peripheral blood
mononuclear cells (PBMNCs) into NOD-scid interleukin
(IL)-2Rgnull (NSG) mice.24 In that model, the severity of
GVHD was closely correlated with the dose of PBMNCs
infused. Here, we investigated the impact of infusion of
clinical-grade enriched Treg on the development of xeno-
geneic GVHD in NSG mice.
MATERIALS AND METHODS
PBMNC collection and Treg enrichment
Before PBMNC collection, each volunteer donor (n = 6)
underwentmedical evaluation toassesshis orher ability to
donateand toexplain theapheresisprocedure. Eachdonor
signed written informed consent (previously approved by
the ethics committee of the CHU of Liege) for undergoing
a leukapheresis for research purposes according to the
standard operating procedures of the Laboratory of Cell
and Gene Therapy. Leukapheresis procedures were per-
formed using peripheral catheters and a continuous-flow
blood cell separator (Cobe Spectra, Terumo BCT, Lake-
wood, CO) and according to a MNC collection proto-
col. The processed blood volume was approximately 2
total blood volumes. Anticoagulation was performed with
ACD-A (ratio 1:12).
Treg were isolated using a system for clinical-grade-
conform large-scale cell separations (CliniMACS system,
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
Clinical-grade reagents were used. CD4+CD25+ Treg were
isolated in a two-phase procedure: simultaneous CD8 and
CD19 depletion followed by CD25-positive selection. In
the first phase, cells were washed, adjusted to 87.5 mL
in phosphate-buffered saline (PBS)-ethylenediaminete-
traacetic acid (EDTA)-0.5% human serum albumin (HSA),
labeled with CliniMACS CD8 and CD19 reagents (Miltenyi
Biotec) for 30 minutes at room temperature on an orbital
shaker, rewashed, and resuspended in 100 to 300 mL of
PBS-EDTA-0.5% HSA (concentration on the CliniMACS
had to be below 4 ¥ 108 cells/mL). CD8- and CD19-labeled
cells were depleted by the 2.1 depletion program of the
CliniMACS instrument (Miltenyi Biotec). After being
washed, the CD8negCD19neg cell fraction was suspended
in 380 mL of PBS-EDTA-0.5% HSA, labeled with CD25
reagents (Miltenyi Biotec) for 15 minutes at 4°C on an
orbital shaker, washed, and resuspended in 100 mL of
PBS-EDTA-0.5% HSA. CD25+ cells were isolated by auto-
matic positive-selection cycles using the 3.1 enrichment
program on the CliniMACSplus device. Aliquots before and
after each labeling, depletion, and enrichment step were
immunophenotyped.
Flow cytometry analyses for Treg enrichment
Analysis of cell surface molecules was performed by mul-
ticolor staining at each step of the cell separation process
using the CliniMACSplus system (first step of double CD8/
CD19 depletion—apheresis product, start product before
CD8/CD19 depletion, discarded and depleted fractions;
second step of CD25-positive selection—start fraction,
positive [Treg-enriched] and negative fractions). The fol-
lowing antibodies specific for human cell surface antigens
were used: CD45-VioBlue, CD8-allophycocyanin (APC),
CD15-phycoerythrin (PE), CD14-PE, CD20-fluorescein
isothiocyanate (FITC), Treg detection kit I (CD4-FITC,
CD25-APC, CD127-PE), Treg detection kit II (CD4-FITC,
CD25-PE, CD45-VioBlue, FoxP3-APC), all from Miltenyi
Biotec. Flow cytometric data were acquired on a flow
cytometer (MACSQuant analyzer, Miltenyi Biotec) and
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analyzed with software (MACSQuantify, Miltenyi Biotec).
A first gate was made on CD45+ cells, a second gate on
forward scatter-side scatter to eliminate cell debris, and
a third gate on viable cells. The percentage of Treg was
then determined as the percentage of cells with either
CD4+CD25+FoxP3+ or CD4+CD25+CD127low phenotype.
The start and Treg-enriched fractions were further
phenotyped by multicolor staining. The following anti-
bodies specific for human cell surface antigens were
used: PercP-conjugated anti-CD4 (SK3 clone, Becton
Dickinson, Franklin Lakes, NJ); PE-conjugated anti-CD25
(4E3 clone, Miltenyi Biotec); biotin-conjugated anti-
CD127 (RDR5 clone, eBioscience, San Diego, CA), anti-
CCR6 (11A9 clone, Becton Dickinson), anti-CCR5 (T21/8
clone, eBioscience) or anti-CCR4 (1G1 clone, Becton
Dickinson); APC-eFluor 780 conjugated anti-streptavidin
(eBioscience); PeCy7-conjugated anti-CCR7 (3D12 clone,
Becton Dickinson); and PE-conjugated anti-CD45RA
(HI100 clone, eBioscience). Two million cells were incu-
bated for 20 minutes at 4°C in the dark with different mix
of antibodies and then washed twice with PBS-3% FBS
(Sigma Aldrich, St Louis, MO). This process was repeated
for a second 15-minute period for the streptavidin
staining step. Human intracellular Foxp3 staining kit
containing AlexaFluor 488 anti-Foxp3 (206D clone),
isotype-matched control IgG, and cell fixation and perme-
abilization solution (Fix/Perm) were purchased from
BioLegend (San Diego, CA). Foxp3 intracellular staining
was performed according to the manufacturer’s instruc-
tions. Datawere acquired on a flow cytometer (FACSCanto
II, Becton Dickinson) and analyzed with software (Flowjo
7.0, Tree Star, Inc., San Carlos, CA). Expression of chemo-
kine receptors (CCR4, CCR5, and CCR6) was evaluated on
both CD4+FoxP3+CD45RA+ and CD4+FoxP3+CD45RA-
Treg.
Suppression assay
For the last two selection procedures, Treg function was
assessed with a 7-hour flow cytometric assay, using sup-
pression by Treg of the activation markers CD69 and
CD154 on responder T cells (CD4+CD25-; activated with
anti-CD3/CD28–coated beads [Dynabeads, Invitrogen,
Gent, Belgium] at a bead/responder T-cell ratio of 0.2), as
described by Canavan and coworkers.25
Signal-joint T-cell receptor excision circles
Naive (CD4+CD25+CD127–CD45RA+CCR7+) andmemory
(CD4+CD25+CD127-CD45RA–) Treg were isolated from
theTreg-enriched fractionofDonor 5by a cell sorter (FACS
ARIA II, Becton Dickinson). Quantification of signal-joint
T-cell receptor excision circles among naive and memory
Treg was assessed as previously described.26,27
Assessment of demethylated FOXP3il sequences
Genomic DNA was prepared from the enriched Treg
fractions with the PureLink genomic DNA mini kit
(Invitrogen). One microgram of genomic DNA was
treated with sodium bisulfite using a bisulfite conversion
kit (EpiTect, Qiagen, Düsseldorf, Germany). Real-time
polymerase chain reaction (PCR) amplification of methy-
lated and demethylated FOXP3i1 sequences was per-
formed on 62.5 ng of bisulfite-converted DNA as
previously described,28 with methyl-specific primers
listed by Lucas and coworkers.29 The proportion of cells
with demethylated FOXP3i1 was calculated as follows:
(number of demethylated FOXP3i1 sequences/(number
of demethylated FOXPi1 sequences + number of methy-
lated FOXP3i1 sequences)) ¥ number of X chromosomes
per cell. The calculated proportions are approximate,
because the methylation-specific quantitative PCR assay
detects only sequences that are either completely dem-
ethylated or completely methylated in the FOXP3i1
region.
Induction of xenogeneic GVHD in NSG mice
All experimental procedures and protocols used in this
investigation were reviewed and approved by the Institu-
tional Animal Care and Use Ethics Committee of the
University of Liège, Belgium (Permit 711). The “Guide for
the Care and Use of Laboratory Animals,” prepared by
the Institute of Laboratory Animal Resources, National
Research Council, and published by the National
Academy Press, was followed carefully. NSG mice (The
Jackson Laboratory, BarHarbor,ME)were given 2.5 GyTBI
using a 137Cs source 1 day before IV injection of either
2 ¥ 106 human PBMNCs (apheresis product, PBMNC
group) alone, IV injection of 2 ¥ 106 humanPBMNCs (aph-
eresis product) plus 1 ¥ 106 CD4+CD25 enriched Treg
(PBMNC + Treg group), or IV injection of 2 ¥ 106 enriched
Treg alone (Treg group). Each group included from five
to seven mice depending on the number of NSG mice
available. All cell products were infused fresh. In the
first experiment, two doses of enriched Treg were tested
(0.5 ¥ 106 and 1 ¥ 106 CD4+CD25 enriched Treg). In the
fourth experiment, all cell doses were doubled. In Experi-
ments 2 through 6, one mouse in each of the three groups
(PBMNCs only, PBMNCs + Treg, and Treg only) was
selected before transplant to be sacrificed around Day 26
(range, Days 25-27) to allow flow cytometric analyses. In
Experiment 4, all mice in the PBMNC-only and the
PBMNC + Treg groups died before Day 26 (and thus no
mouse could be euthanized onDay 26). Further, in Experi-
ments 3 and 6, the mice in the PBMNC group scheduled
for necropsy on Day 26 died earlier and were then
replaced randomly by two other PBMNC mice. Mice who
suffered from terminal stage of xenogeneic GVHD were
euthanized.
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Detection of human engraftment by flow cytometry
At the time of necropsy, peripheral blood (PB), spleen,
and bone marrow (BM) were harvested and analyzed by
flow cytometry. Splenocytes were obtained by crushing
the spleen, and BM cells by flushing femurs and tibiae.
Cells were counted in a hematology analyzer (XS-800i,
Sysmex, Hoeilaart, Belgium). The PB was depleted of
red blood cells using the RBC lysis buffer (eBiosciences)
according to the manufacturer’s instructions. The follow-
ing antibodies specific for human cell surface antigens
were used: Horizon v500-conjugated anti-CD3 (SP34-2
clone, Becton Dickinson); efluor 450–conjugated anti-
CD4 (RPA-T4 clone, eBioscience); APCCy7-conjugated
anti-CD8 (SK1 clone, Becton Dickinson); PercP-
conjugated anti-CD45 (2D1 clone, Becton Dickinson);
PE-conjugated anti-CD25 (BC96 clone, eBioscience),
PeCy7-conjugated anti-CCR7 (3D12 clone, Becton Dickin-
son), APC-conjugated anti-CD45RA (HI100 clone, Becton
Dickinson), biotin-conjugated anti-CCR4 (1G1 clone,
Becton Dickinson), and APC-eFluor 780–conjugated anti-
streptavidin (eBiosciences). Cells (1.5 ¥ 106-2 ¥ 106 cells/
sample) were incubated with antibodies or isotype-
matched control IgG (all MOPC 21 clone, Becton
Dickinson) for 20 minutes at 4°C in the dark. Cells were
washed twice with PBS-3% FBS (Lonza, Verviers,
Belgium). Human Foxp3 staining was performed as
described above. Percentage of Treg was identified based
on the CD4+CD25+FoxP3+ phenotype on the total lym-
phocyte gate. Data were acquired on a flow cytometer
(FACSCanto II, Becton Dickinson) and analyzed with soft-
ware (Flowjo 7.0, Tree Star, Inc.).
Histology and immunochemistry
Lungs from mice euthanized on Days 25 to 27 after trans-
plantation (onemouse in each group from Experiments 2,
3, 5, and 6) were harvested, washed with PBS, fixed in
10% formalin (Sigma Aldrich), and routinely processed
for paraffin embedding. Five-micrometer sections were
stained with hematoxylin-eosin for histologic examina-
tion. Xenogeneic GVHD in lung sections was assessed
in a semiquantitative fashion as described by Nervi and
colleagues.30
Statistical analyses
The Mann-Whitney test was used to compare homing
receptor expression between naive and memory Treg and
between lymphocyte subsets at necropsy in mice from
different groups. Survival curves were modeled using the
Kaplan-Meier methods. Comparisons between groups
were made with the log-rank test. The impact of Treg infu-
sion on survival was also assessed in a multivariate Cox
model including group (PBMNC vs. PBMNC + Treg) and
experiment number (1 vs. 2 vs. 3 vs. 4 vs. 5 vs. 6) as cova-
riates. All p values were two sided. p values less than
0.05 were considered as significant. Statistical analyses
were carried out with computer software (GraphPad
Prism, GraphPad Software, SanDiego, CA; and SASVersion
9.2 for Windows, SAS Institute, Cary, NC).
RESULTS
Selection of Treg: phenotypic features
The initial leukapheresis product contained a median
of 153 ¥ 108 (range, 83 ¥ 108-293 ¥ 108) viable white blood
cells (WBCs). A median of 17.7 ¥ 108 viable WBCs were
taken from the leukapheresis product for mouse experi-
ments and for analysis. Due to a technical problem
(incomplete collection bag connection to the column)
during the sixth selection procedure, 31% of the leuka-
pheresis productwas lost. As seen inTable 1, this technical
problem dramatically impacted the purity of the selected
Treg, probably because too few cells were loaded onto
the column for the first and thus the second step of the
procedure. Hence, the starting fraction of the six experi-
ments contained a median of 129 ¥ 108 (range, 54 ¥ 108-
276 ¥ 108) viable WBCs. After the two-step selection
procedure, a median of 1.8 ¥ 108 (range, 0.7 ¥ 108-
2.3 ¥ 108) viable cells were recovered.Themedian percent-
age of CD4+CD25+CD127dim/low and CD4+CD25+FoxP3+
cells in the final products were 79 (range, 52-82) and 66
(range, 42-68), respectively, with consistently lower figures
in the sixth experiment. The final fraction contained vir-
tually no monocytes, B cells, nor CD8+ T cells. Finally, we
also measured the proportion of demethylated FOXP3
Intron 1 (FOXP3i1) sequences. Demethylation of this
regulatory region of gene FOXP3 is considered the most
specific marker of human Treg, because in contrast to
protein FOXP3, it is not found in activated non-Treg. The
proportions of demethylated FOXP3i1 sequences in the
Treg-enriched fractions were 42.5 and 32.4%, in Experi-
ments 5 and 6, respectively.
We then further examined the Treg phenotype in
the Treg-enriched fraction. Thirty-six percent (range,
20%-36%) of Treg had a naive phenotype (defined
as CD4+FoxP3+CD45RA+ T cells), while 64% (range,
64%-80%) had a memory phenotype (defined as
CD4+FoxP3+CD45RA–). To assess the maturation and
migratory capacities of Treg, we also analyzed expression
of homing receptors by Treg subsets. CCR4, CCR5, and
CCR6 homing receptors were expressed in 16.5% (range,
8.3%-23.4%), 1.7% (range, 1.1%-7.0%), and 16.7% (range,
6.5%-27.2%) of naive Treg, versus in 88.2% (range, 83.3%-
91.8%; p = 0.008), 27.5% (range, 23.6%-32.4%; p = 0.008),
and73.4%(range, 64.5%-83.5%;p = 0.008)ofmemoryTreg,
respectively. As expected, naive Treg contained higher
T-cell receptor excision circles (TRECs) amount than
memoryTreg (1967 vs. 85 TRECS/105 cells) in the products
from Donor 5.
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Treg coinfusion delayed experimental
xenogeneic GVHD
As previously observed,24 the timing of GVHD occurrence
varied from donor to donor (Fig. 1). Importantly, infusion
of Treg-enriched cells delayed xenogeneic GVHD in
the first five experiments in a Cox model adjusted for
experiment number (hazard ratio [HR], 0.19; 95% confi-
dence interval [CI], 0.10-0.38; p < 0.0001). Specifically,
the median survival in the PBMNC group versus the
PBMNC + Treg group was 30 versus 56 days (p = 0.015) in
Experiment 1, 117 versus more than 162 days (p = 0.136)
in Experiment 2, 26 versus 70 days (p = 0.013) in Experi-
ment 3, 13 versus 16 days (p = 0.038) in Experiment 4, and
27 versus 49 days (p = 0.059) in Experiment 5. In the first
experiment, we also tested two ratios of PBMNCs/Treg
(2/1 and 4/1), and as shown in Fig. 1A, there was no
difference in survival between the two ratios (median
survival 56 days vs. 55 days). In the sixth cohort, Treg-
enriched coinfusion failed to delay experimental xenoge-
neic GVHD (the median survival was 46 days in the
PBMNC group vs. 48 days [p = 0.337] in the PBMNC + Treg
group). This could be related to the low purity of the Treg-
enriched fraction due to a technical problem (see above)
that also resulted in a higher number of conventional
PBMNCs infused. Nevertheless, in the Cox model taking
into account data from the six experiments, survival
remained significantly higher in the PBMNC + Treg group
than in the PBMNC group (HR, 0.34; 95% CI, 0.19-0.62;
p = 0.0004).
In Experiments 2, 3, 5, and 6 (in Experiment 4, mice
died before Day 26), one mouse from each of the PBMNC,
PBMNC + Treg, and Treg groups (each selected before
transplantation) were euthanized on Days 25 to 27
(depending on experiments, medianDay 26.5) after trans-
plantation. There were no significant differences between
the PBMNC and the PBMNC + Treg groups for infiltration
by human CD45+CD3+ cells in the blood (median, 60.2%
[range, 7.8%-64.6%]) in the PBMNC group versus 23.4%
[range, 1.6%-43.6%] in the PBMNC + Treg group), spleen
(median, 11.9% [range, 7.3%-50.4%]) in the PBMNC group
versus 14.1% [range, 2%-28.7%] in the PBMNC + Treg
group), and BM (median, 10.7% [range, 0.3%-19.1%]) in
the PBMNC group versus 3.2% [range, 0.1%-10.9%] in the
PBMNC + Treg group). The frequency of T-cell subsets
(CD4 and CD8) as well as their mitotic activity (assessed
by KI67 expression) in the PB, spleen, and BM were com-
parable in PBMNC and PBMNC + Treg mice (Fig. 2A-C).
Interestingly, the frequency of Foxp3+ cells among total
TABLE 1. Phenotypical status of Treg*
Experiment
Parameter 1 2 3 4 5 6†
Donor age (years) 44 31 34 38 29 26
Apheresis product
Viable WBCs (¥108) 103 293 185 122 203 83
CD4 (%) NA NA NA 35.3 42.4 34.1
CD8 (%) NA 21.9 23.5 21.3 21.7 24.3
CD4+CD25high (%) NA NA NA 2.4 3 2.4
CD4+CD25+CD127- (%) NA NA NA 2.4 3.2 2.5
CD4+CD25+FoxP3+ (%) NA NA NA 2 2.9 1.7
Demethylated FOXP3i1 sequences (%) 1.0 0.7
Start fraction
Viable WBCs (¥108) 90.6 275.5 149.4 108 185 53.7
After the two-step procedure
Viable WBC (¥108) 2.0 2.0 1.5 1.6 2.3 0.7
CD4 (%) 94.5 98.5 97.9 98.4 96.7 97.0
CD8 (%) 0 NA NA NA 0.004 0.03
CD4+CD25high (%) NA 77.5 72.6 70.7 74.1 52.2
CD4+CD25+CD127- (%) NA 82.5 79.2 77.3 80.1 52.3
CD4+CD25+FoxP3+ (%) 58.8‡ 64.7 67.4 68.2 67.9 42.4
% of CD4+CD25+FoxP3+ recovery after the two-step procedure (yield)§ NA NA NA 44.7 26.5 21
Demethylated FOXP3i1 sequences (%) 42.5 32.4
Suppression assay¶
CD69 (%) 8.5/27.0 0.4/11.3
CD154 (%) 19.0/49.2 14.7/30.7




§ Somewhat underestimated because a median of 17.7 ¥ 108 viable WBCs was taken from the leukapheresis product for mouse experi-
ments and for analysis; NA = not available.
¶ The two values shown in each column represent the percentage decrease (in comparison to expression in the absence of Treg) of the
expression of activation markers (CD69 and CD154) by CD25- T cells activated with anti-CD3/CD28–coated beads, in presence of Treg
with two CD25–:Treg cells ratios (2:1/1:1).25
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human CD45+CD3+CD4+ cells was similar in the PBMNC
compared to the PBMNC + Treg groups, that is, 2.1%
(range, 0.2%-3.1%) versus 3.6% (range, 0.8%-9.5%) in the
spleen, 1.8% (range, 1.4-4.3%) versus 0.8% (range, 0.1%-
15.4%) in the BM, and 1.3% (range, 0.5%-4.5%) versus
1.1% (range, 0.4%-10.8%) in the blood (Fig. 2D). Finally,
histologic signs of xenogeneic GVHD
in the lungs on Day 26 were similar in
the PBMNC and PBMNC + Treg groups
(Table 2) and were relatively mild, prob-
ably because histology was performed
relatively soon after transplantation.
Fate of Treg-enriched fraction
infused alone in NSG mice
Infusion of the Treg-enriched fractions
in NSGmice given 2.5 Gy TBI on Day -1
was safe with only one of 21 mice dying
during the study period (>120 days after
transplantation) of unknown cause
and none of themice experiencing clini-
cal GVHD (Figs. 3 and 4A; there was,
however, some histologic evidence of
lung GVHD in Treg mice scheduled to
be euthanized on Day 26). In Experi-
ments 2, 3, 5, and 6, one mouse
(selected before transplantation) was
euthanized between Days 25 and 27
(median, Day 26.5) after transplanta-
tion. At necropsy, infiltration by human
CD45+CD3+, CD45+CD3+CD4+, and
CD45+CD3+CD8+ cells was, respec-
tively, 0.5% (range, 0.3%-8.1%), 0.4%
(range, 0.3%-7.9%), and 0% (range,
0%) in the blood; 0.6% (range, 0.4%-
13.4%), 0.2% (range, 0%-12.1%), and
0.4% (range, 0.2%-0.7%) in the spleen;
and 0.2% (range, 0.2%-1.3%), 0.2%
(range, 0%-1.1%), and 0% (range
0%-0.1%) in the BM. Interestingly,
the percentage of CD25+Foxp3+ cells
among total human CD45+CD3+CD4+
cells was very low, that is, 2.1% (range,
1.9%-12.5%) in the spleen, 3.1% (range,
0.5%-3.2%) in the BM, and 12.2% (range,
1%-24.9%) in the blood (Fig. 4B).
Further, among CD4+ T cells in the
spleen, the vast majority of CD4+ T cells
were memory CD4+ T cells (median,
97%; range, 84%-97%).
The remaining mice were eutha-
nized at the end of the study period
(124-166 days after transplantation).
Infiltrations by human CD45+CD3+,
CD45+CD3+CD4+, and CD45+CD3+CD8+ cells were,
respectively, 0.2% (range, 0%-12.6%), 0.7% (range,
0%-6.5%), and 0% (range, 0%-2.6%) in the blood; 2.9%
(range, 0.1%-51.1%), 1.1% (range, 0%-34.5%), and 0.6%
(range 0%-4.7%) in the spleen; and 0.2% (range, 0%-5.6%),
0.15% (range, 0%-4.4%), and 0% (range, 0-0.7%) in the BM.
Fig. 1. Impact of Treg coinfusion on xenogeneic GVHD in NSG mice given human
PBMNCs IV after 2.5 Gy TBI the day before transplantation. Continuous lines repre-
sent mice given PBMNCs only (PBMNC mice) while broken lines mice given PBMNCs
and enriched Treg (Treg + PBMNC mice). Mice that were euthanized around Day 26
(Days 25-27) for flow cytometry analyses were censored on the graft. In all experi-
ments but Experiment 4, a total of 2 ¥ 106 PBMNCs were infused in PBMNC mice,
while 2 ¥ 106 PBMNCs + 1 ¥ 106 Treg were infused in Treg + PBMNC mice. In Experi-
ment 1, another ratio of PBMNCs and Treg (4/1) was also tested (gray broken line in
Fig. 2A). For Experiment 4, all cell doses were doubled. As mentioned in the text, due
to a technical problem, the purity of enriched Treg in Experiment 6 was low (42% of
CD4+CD25+FoxP3+ T cells). Graphs A through F show results in Experiments 1
through 6, respectively. Taking data from the six experiments, survival was signifi-
cantly shorter in the PBMNC group than in the PBMNC + Treg group (HR, 0.34;
95% CI, 0.19-0.62; p = 0.0004) in a Cox model adjusted for the different
experiments.
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DISCUSSION
Treg infusion is one of the most promising nonpharmaco-
logic approaches for GVHD prevention or treatment.
However, isolating a pure population of Treg in sufficient
amount for clinical use has remained challenging (outside
of the HLA-haploidentical setting where very few conven-
tional T cells are transplanted).16,22,31,32 Some groups of
investigators are focusing their research on ex vivo Treg
expansion.23,31 While this approach could yield sufficient
Treg numbers with very good purity whenmTor inhibitors
are added to the culture media, the fate of ex vivo
expanded Treg after infusion in humans has remained
poorly understood, although Brunstein and colleagues23
could detect ex vivo expanded (without mTor inhibition)
Treg in the PB up to 14 days after infusion in the context of
unrelated cord blood transplantation. Further potential
limitations of Treg ex vivo expansion include reduction
in their T-cell repertoire, as well as possible expansion of
Th17 cells when ex vivo expansion is carried out without
mTor inhibitors.33 In addition, given that mTor inhibitors
also induce FoxP3 on conventional T cells,34 Treg ex vivo
expansion in the presence of mTor
inhibitors does not exclude the risk of
a contamination by induced Treg that
could revert in vivo, in the absence of
in vivo mTor inhibition.31 Thus, another
approach might consist of infusing a
less pure population of freshly isolated
Treg (obtained by clinical-grade immu-
nomagnetic selection),35,36 followed by
in vivo selection or expansion with
sirolimus and/or low-dose IL-2,37,38 thus
avoiding the need for culturing Treg ex
vivo in good manufacturing practice
conditions. However, before propos-
ing this easier approach to patients
with steroid-refractory chronic GVHD,
we wanted to investigate the ability of
clinical-grade enriched Treg to attenu-
ate experimental xenogeneic GVHD
induced by PBMNC (autologous toTreg)
infusion in NSG mice. Given that the
purity of the enriched fraction was
not 100%, it was also necessary to verify
their inability to induce xenogeneic
GVHD when infused alone. Several
observations were made.
First, this report confirms the
chosen combined negative and posi-
tive separation strategy to select Treg
performed by using the CliniMACSplus
system (device and reagents) allows
recovery of a large number of enriched
CD4+CD25+FoxP3+ T cells, with a
median purity ranging from 42% to 68%.
This is in line with what was observed by other groups
of investigators.22 Interestingly, we also demonstrated in
sorted cells from Donor 5 that naive Treg (in comparison
to memory Treg) were markedly enriched for recent
thymus emigrants expressing more than 20 times more
TRECs per 105 cells.
Second andmore importantly, coinfusion of enriched
Treg at a PBMNC/Treg-enriched ratio of 2/1 (with a real
non-Treg/Treg [defined as CD4+CD25highFoxP3+] ratio
ranging from 2.5 to 3.3) delayed the development of xeno-
geneic GVHD and prolonged survival. These results are in
line with two previous reports demonstrating that coinfu-
sion of fresh CD25+ T cells or of expanded Treg (with a
purity of 70%) attenuated xenogeneic GVHD caused by
infusion of PBMNCs (autologous to Treg) in another defi-
cient mouse strain (Rag2–/–gammaC–/– mice).39,40 Our
results are also in line with those observed by Hippen and
colleagues41 and by Chakraborty and colleagues42 who
demonstrated that coinfusion of expanded Treg at a
PBMNC/Treg ratioof 1/1decreasedxenogeneicGVHDand
increased survival of NSGmice.The originality of ourwork
Fig. 2. (A-C) Frequency of T-cell subsets (CD4 and CD8) as well as their mitotic activ-
ity (assessed by KI67 expression) on Day 26 after transplantation in spleen (A), PB
(B), and BM (C) of NSG mice given (◊) or not (•) Treg in addition to PBMNCs. ( )
Data from the PBMNC + Treg mouse in Experiment 6. (D) Percentage of human
Foxp3+ cells among total human CD45+CD3+CD4+ cells in spleen, BM, or PB on Day
26 after transplantation in mice given (◊) or not (•) Treg in addition to PBMNCs.
Horizontal lines represent median values of each group. Due to a technical problem,
data for the spleen of PBMNC group in Cohort 5 are missing (A and D).
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in comparison with those previous reports is that we
used freshly isolated Treg (using clinical-grade compliant
method) and not expanded Treg. Although Treg-enriched
infusion attenuated xenogeneic GVHD in our study, they
only provided a temporary protection from xenogeneic
GVHD since most mice who survived beyond Day 75 after
PBMNC/Treg coinfusion eventually developed signs of
“xenogeneic chronic GVHD” (skin fibrosis and hair loss
[Fig. 3]).This couldbedue to a larger expansionof conven-
tional T cells compared to that of Treg in ourmodel (in line
with the apparent disappearance of Treg when infused
alone inNSGmice) or to the fact thatweused a suboptimal
ratio of PBMNC/Treg (for example the PBMNC/Treg ratio
in the study byDi Ianni and coworkers22 was 1/2 instead of
2/1 in current study). Further studies are needed to assess
whether approaches combining Treg infusion with rapa-
mycin or low-dose IL-2 will allow to totally abrogate xeno-
geneicGVHD in thismodel and to assess the impact ofTreg
infusion on engraftment of human hematopoietic stem/
progenitor cells in NSGmice.
Third, infusion of the Treg-enriched fraction alone
did not induce xenogeneic GVHD, even in the sixth cohort
where Treg purity was only 42% and
mice thus received more than 1 ¥ 106
conventional CD4+T cells. Interestingly,
cells from Treg-enriched fractions when
infused alone not only did not cause
GVHD, but also did not expand (or if
they expanded underwent apoptosis),
as shown by the very low human cell
infiltration in NSG mice observed at
necropsy. A probable explanation is that
Treg inhibited in vivo the conventional
activated CD4+ T cells contained in the
Treg-enriched fraction, while true Treg
did not expand probably due to a lack of
human IL-2 in that model when only
enriched Treg are infused, as observed
in a recent report from Abraham and
colleagues.43 Further, clinical studies have demonstrated
that, after allo-HCT, infusion of CD8-depleted donor lym-
phocytes induced less acute GVHD than infusion of
unmanipulated DLI,44 suggesting that CD4+ T cells were
less prone to induce GVHD than CD8+ T cells in humans.
In summary, our data suggest that infusion of clinical-
grade enrichedTreg delayed the occurrence of xenogeneic
GVHD induced by human autologous PBMNCs (at a
PBMNC/enriched Treg ratio of 2/1) in NSG mice, at least
when Treg purity in the Treg-enriched fraction was
more than 55%. Based on these results, a pilot study of
CliniMACS-enriched donor Treg infusion together with in
vivo selection with rapamycin is under development as
treatment for patients with steroid-refractory chronic
GVHD.
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